Publications by authors named "Hui-Zhou Li"
Article Synopsis
- Paclitaxel, an anti-cancer drug, triggers cognitive impairment by inducing necroptosis—a type of programmed cell death—in hippocampal neurons, linked to the RIPK1-RIPK3-MLKL signaling pathway.
- Flow cytometric analysis revealed that paclitaxel-treated cells showed a higher incidence of necroptosis, marked by increased cell death and altered cell structure compared to control cells.
- The use of necrostatin-1, an inhibitor of RIPK1, not only reduced necroptosis in cultures but also improved cognitive function in mice treated with paclitaxel, suggesting that targeting necroptosis may be a therapeutic strategy to mitigate cognitive side effects of cancer treatment.
CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation.
Biochim Biophys Acta Mol Basis Dis
December 2024
The immune landscape of distant unablated tumors following insufficient microwave ablation (iMWA) in hepatocellular carcinoma (HCC) remains to be clarified. The objective of this study is to define the abscopal immune landscape in distant unablated tumor before and after iMWA for HCC. Two treatment-naive patients were recruited for tumor tissue sampling, of each with two HCC lesions.
View Article and Find Full Text PDFArticle Synopsis
- Paclitaxel (PTX) is a common chemotherapy drug that can cause peripheral neuropathy (PIPN), negatively impacting patients' quality of life, and its mechanism involves necroptosis of dorsal root ganglion neurons.* -
- The study used rat models to demonstrate that PTX triggers necroptosis through increased expression of RIP3 and MLKL proteins, which can be inhibited by necrostatin-1 (Nec-1).* -
- Additionally, the drug minocycline was shown to reduce PTX-induced microglial polarization and subsequently lower the levels of necroptosis markers, improving pain symptoms in the rats, indicating a new potential strategy for treating PIPN.*
To improve the survival of patients with hepatocellular carcinoma (HCC), new biomarkers and therapeutic targets are urgently needed. In this study, the GEO and TCGA dataset were used to explore the differential co-expressed genes and their prognostic correlation between HCC and normal samples. The mRNA levels of these genes were validated by qRT-PCR in 20 paired fresh HCC samples.
View Article and Find Full Text PDFObjective: This study aimed to investigate the effect of resveratrol (Res) on paclitaxel (PTX)-induced cognitive impairment and elucidate the underlying molecular mechanisms.
Methods: Morris Water Maze (MWM) test was used to evaluate the mice's spatial learning and memory abilities. Western blotting was applied to detect protein expression of receptor-interacting protein (RIP3), mixed lineage kinase domain-like protein (MLKL), silencing information regulator 2 related enzyme 1 (SIRT1), peroxisome proliferator activated receptor coactivator-1 (PGC-1α), NADPH oxidase 2 (NOX2), NOX4, postsynaptic density zone 95 (PSD95), arginase-1 (Arg-1) and inducible nitric oxide synthase (iNOS).
Purpose: Transarterial chemoembolization (TACE) is recommended in patients with unresectable HCC beyond the Milan criteria (MC). However, the long-term efficacy of TACE remains unsatisfactory. Percutaneous microwave ablation (MWA) is a curative therapy for early-stage HCC that provides better local tumor control than TACE; however, MWA is limited for large or multifocal lesions.
View Article and Find Full Text PDFArticle Synopsis
- * Dex treatment improved learning and memory deficits caused by I/R, while Oxy did not show significant benefits; both drugs reduced certain inflammatory markers and pathways associated with microglial polarization in the brain.
- * Dex also influenced synaptic transmission by decreasing the expression of NR2B and the activity of excitatory synaptic currents, suggesting its potential in mitigating cognitive disorders post-I/R injury, while further studies are needed to clarify its mechanisms.
Background: To compare the efficacy and safety between conventional transarterial chemoembolization (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with infiltrative hepatocellular carcinoma (iHCC).
Methods: A total of 89 iHCC patients who were treated with either cTACE (n = 33) or DEB-TACE (n = 56) between April 2013 and September 2017 were included in this retrospective study. Patients with the situations that might have a poor outcome were defined as advanced disease including Child-Pugh class B, bilobar lesions, tumor size greater than 10 cm, ECOG 1-2, tumor burden of 50-70%, and the presence of ascites, arterioportal shunt (APS), and portal venous tumor thrombus (PVTT).